SubsidieMeestersBeta-cell recovery to counter diabetes
DiogenX aims to cure Type 1 Diabetes by regenerating pancreatic beta-cells for autonomous insulin release, with plans to out-license the drug following human clinical proof by 2026.
Projectdetails
Introduction
Globally, 8.75 million people with T1D rely only on insulin administration to manage the symptoms of their disease. The treatment is complex since it requires injecting insulin (2-4 times/day) and adhering to a restrictive lifestyle (e.g., following a strict diet), reducing patient quality of life (QoL).
Challenges in Current Treatment
Even with insulin, less than 20% of patients achieve their target glucose level. This inadequacy eventually leads to vascular complications, such as:
- Stroke
- Renal disease
These complications reduce life expectancy by 10-15 years.
DiogenX's Mission
DiogenX aims to withdraw insulin dependency and cure T1D by regenerating pancreatic beta-cells to allow autonomous insulin release in response to blood glucose level increases.
Future Plans
We expect to out-license our drug to a pharma company. Some of them have already manifested their interest and invested in the capital of DiogenX. This may materialize as soon as clinical proof of principle is demonstrated in humans, which will be reached in 2026.
Funding and Timeline
The proceeds from Series A, to be raised in 2023, are 80% secured.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 5.673.000 |
Tijdlijn
| Startdatum | 1-10-2023 |
| Einddatum | 30-9-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- DIOGENX SASpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scaleDeveloping a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support. | EIC Accelerator | € 2.500.000 | 2022 | Details |
The first universal and price-neutral insulin penGO-Pen ApS aims to refine and scale the UNIPEN, an affordable and refillable insulin injection system, to improve dosing accuracy for over 13 million people with diabetes. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes. | EIC Accelerator | € 2.500.000 | 2023 | Details |
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune systemi-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028. | EIC Accelerator | € 2.495.510 | 2023 | Details |
The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale
Developing a non-invasive glucose monitoring device to improve diabetes management and prevent onset for over 2 billion people through EIC blended finance support.
The first universal and price-neutral insulin pen
GO-Pen ApS aims to refine and scale the UNIPEN, an affordable and refillable insulin injection system, to improve dosing accuracy for over 13 million people with diabetes.
Clinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology.
GLIX1, a novel therapy targeting deregulated mechanisms in GBM, shows promising tumor regression in preclinical studies and aims for clinical validation to improve patient outcomes.
The i-Thymus: wielding the potential of gene therapy, cell therapy and induced pluripotent stem cells for the regeneration of the thymus and the adaptive immune system
i-Thymus aims to revolutionize treatment for babies born without a thymus by using gene therapy to create implantable thymus organoids, targeting clinical trials and market entry by 2028.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Deciphering cellular and molecular mechanisms of β-cell regenerationBetaRegeneration aims to develop targeted therapies for diabetes by enhancing beta-cell protection and regeneration through novel druggable targets and combinatorial approaches. | ERC Advanced... | € 2.446.645 | 2022 | Details |
Universal 3D printer bioink for Type 1 diabetes cell therapyUniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment. | ERC Proof of... | € 150.000 | 2024 | Details |
Mind Game DM2 (MGDM2)Het project richt zich op het verbeteren van de kwaliteit van leven van diabetespatiënten door een integrale leefstijlinterventie en koolhydraatarm dieet, met als doel duurzame mindsetverandering en herstel. | Mkb-innovati... | € 20.000 | 2020 | Details |
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated DiabetesThis project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications. | EIC Pathfinder | € 3.885.462 | 2023 | Details |
Pharmacoepigenetics for precision medicine in type 2 diabetesPROCEED aims to develop and commercialize blood-based epigenetic markers to predict metformin response in Type 2 diabetes patients, enhancing personalized therapy and clinical decision-making. | ERC Proof of... | € 150.000 | 2023 | Details |
Deciphering cellular and molecular mechanisms of β-cell regeneration
BetaRegeneration aims to develop targeted therapies for diabetes by enhancing beta-cell protection and regeneration through novel druggable targets and combinatorial approaches.
Universal 3D printer bioink for Type 1 diabetes cell therapy
Uniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment.
Mind Game DM2 (MGDM2)
Het project richt zich op het verbeteren van de kwaliteit van leven van diabetespatiënten door een integrale leefstijlinterventie en koolhydraatarm dieet, met als doel duurzame mindsetverandering en herstel.
Unobtrusive Continuous Multi-Metabolite Monitoring for a Physiological Care of Insulin-treated Diabetes
This project aims to revolutionize diabetes management through a fully implantable multi-metabolite monitoring system and automated insulin delivery, enhancing metabolic health and reducing complications.
Pharmacoepigenetics for precision medicine in type 2 diabetes
PROCEED aims to develop and commercialize blood-based epigenetic markers to predict metformin response in Type 2 diabetes patients, enhancing personalized therapy and clinical decision-making.